The seed round was backed by angel investors including Craig Pollard.
"If you understand the interests of your customers and the best methods to communicate with them through those interests, combined with a pinpoint understanding of exactly which partnerships your marketing budget will allow you to create and which of those opportunities mirror the beliefs that you as a business want to project to the world, then you have the foundations of successful sponsorship."
The pre-seed investment from LYVA Labs will accelerate product development and commercialisation.
"LYVA Labs is delighted to back Sam, Martin and Richard in their mission to help reduce the number of people dying from blood cancer by providing the technology to allow more rapid diagnosis which will enable earlier treatment for the condition."
YFM Equity Partners led the Series A round to support product development and international growth.
"We founded Xapien to bring transparency to business relationships, so that organisations of all sizes can truly know who they are working with. This investment will not only accelerate our cutting edge natural language processing and entity resolution technologies but also positions us at the forefront of a fundamental shift in compliance. We are transforming due diligence from a time-consuming, manual process into an efficient, precise, and comprehensive solution. Xapien is setting new standards in compliance, helping organisations worldwide to navigate complex regulatory environments with ease and confidence, ultimately creating better business practices and stronger ethical standards."
The round was jointly led by Mercia Ventures and Smedvig Ventures to power product development and international growth.
"It is widely accepted that human error is the most prevalent vector for cyber-attacks and is poorly protected against by ineffective training programmes. Advanced analytics applied to real-time behavioural data presents an original approach for CISOs to control human cyber risk. CultureAI is pioneering this with its market-leading software, offering immediate visibility and mitigation of vulnerabilities. James has an incredible reputation as a thought leader in the space and we are excited to partner with him and his team alongside Mercia Ventures."
The financing round featured backing from investors including AstraZeneca, Hitachi Ventures, and Leaps by Bayer.
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
— Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing